Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Elicio Therapeutics Inc
(NQ:
ELTX
)
4.260
-0.420 (-8.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Elicio Therapeutics Inc
< Previous
1
2
3
Next >
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?
June 28, 2024
Elicio Therapeutics announced promising preliminary data from the AMPLIFY-7P Phase 1a study of ELI-002 7P, showing extended median disease-free survival in patients with mKRAS-driven solid tumors.
Via
Benzinga
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
June 28, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?
June 28, 2024
Elicio Therapeutics stock is down on Friday after the company announced a proposed public offering for shares of ELTX this morning.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
June 28, 2024
Pre-market stock movers are a hot topic on Friday and we're breaking down all of the latest news sending shares higher and lower!
Via
InvestorPlace
First Patient Dosed In Phase 2 Study Of Elicio Therapeutics’ ELI-002 7P
February 01, 2024
--News Direct--
Via
News Direct
Elicio Therapeutics Announces Proposed Public Offering
June 27, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
June 27, 2024
ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal adenocarcinoma
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors
June 10, 2024
Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors
Via
News Direct
12 Health Care Stocks Moving In Thursday's Intraday Session
May 16, 2024
Via
Benzinga
ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024
May 15, 2024
ELTX stock results show that Elicio Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry
April 11, 2024
Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry
Via
News Direct
12 Health Care Stocks Moving In Friday's After-Market Session
April 05, 2024
Via
Benzinga
Unlocking the Power of Immunotherapy: Elicio Therapeutics’ (NASDAQ: ELTX) Novel AMP Platform
April 05, 2024
--News Direct--
Via
News Direct
Topics
Death
Exposures
Death
ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023
April 02, 2024
ELTX stock results show that Elicio Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Benzinga's 2024 Virtual Healthcare: What's Next In Health?
March 19, 2024
The 2024 Benzinga Virtual Healthcare Summit brings together top healthcare professionals and companies to discuss industry trends, advancements in technology, and the future of healthcare. Don't miss...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 07, 2024
Via
Benzinga
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy
February 06, 2024
--News Direct--
Via
News Direct
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 05, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Announces Publication Of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy
February 05, 2024
A clinical-stage biotechnology company has published promising preclinical data in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR).
Via
Benzinga
First Patient Dosed In Phase 2 Study Of Elicio Therapeutics' ELI-002 7P
January 31, 2024
A phase 2 trial by a clinical-stage biotechnology company is kicking into full gear.
Via
Benzinga
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics' AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002
January 30, 2024
--News Direct--
Via
News Direct
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics' AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002
January 29, 2024
Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) are the second and
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 29, 2024
Via
Benzinga
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
January 25, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 24, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
January 22, 2024
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit